drugset / Trial / NCT01300234

Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)

NCT01300234

Phase 3 Completed 512 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multi-centre, double blind, double dummy, randomised, controlled study to evaluate the efficacy and safety of TDF 300mg QD versus ADV 10mg QD in Chinese subjects with CHB. This study is designed to demonstrate the superiority of TDF 300mg QD over ADV 10mg QD in treating Chinese subjects with CHB (hepatitis B e antigen \[HBeAg\] positive subjects and HBeAg negative subjects). It will also provide long-term efficacy and safety data (up to 240 weeks) for TDF 300 mg administered once daily.

Timeline

Start
2011-03-30
Primary completion
2012-10-17
Completion
2016-12-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adefovir dipivoxil Small molecule 10 mg
Subject Tenofovir disoproxil fumarate Small molecule 300 mg